CLINICAL TRIALS PROFILE FOR CEPHALEXIN

All Clinical Trials for cephalexin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003824 ↗	S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer	Terminated	National Cancer Institute (NCI)	Phase 3	1999-04-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of ciprofloxacin with that of cephalexin in preventing recurrence of cancer in patients who are undergoing surgery for bladder cancer.
NCT00003824 ↗	S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer	Terminated	Southwest Oncology Group	Phase 3	1999-04-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of ciprofloxacin with that of cephalexin in preventing recurrence of cancer in patients who are undergoing surgery for bladder cancer.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Johnson & Johnson	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Society for Pediatric Dermatology	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Northwestern University	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00187759 ↗	Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection	Completed	University of California, San Francisco	N/A	2004-11-01	This study is to determine whether antibiotic therapy is needed for patients with non-life threatening soft tissue infections. Most patients with these soft tissue infections are presently treated with antibiotics. Many of these infections resolve without proper antibiotic treatment. Treatment of patients with antibiotics after surgical drainage of an abscess may not be necessary and indiscriminate use of antibiotics may lead to colonization by drug-resistant organisms. Subsequent infection by drug resistant organisms may limit the choice of antibiotics in more complicated infections. A comparison between antibiotic treatment and no antibiotic treatment in surgically treated, uncomplicated soft tissue infections is needed to address this very important question.

Clinical Trial Conditions for cephalexin

Condition Name

Condition Name for cephalexin
Intervention	Trials
Cellulitis	6
Surgical Site Infection	5
Anti-Infective Agents	4
Healthy Volunteers	4

Condition MeSH

Condition MeSH for cephalexin
Intervention	Trials
Infections	12
Infection	11
Communicable Diseases	9
Surgical Wound Infection	8

Clinical Trial Locations for cephalexin

Trials by Country

Trials by Country for cephalexin
Location	Trials
United States	74
France	14
Mexico	8
Canada	8
Taiwan	3

Trials by US State

Trials by US State for cephalexin
Location	Trials
California	8
Pennsylvania	7
Maryland	5
Missouri	4
Texas	4

Clinical Trial Progress for cephalexin

Clinical Trial Phase

Clinical Trial Phase for cephalexin
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	1
Phase 4	19

Clinical Trial Status

Clinical Trial Status for cephalexin
Clinical Trial Phase	Trials
Completed	31
Recruiting	11
Not yet recruiting	7

Clinical Trial Sponsors for cephalexin

Sponsor Name

Sponsor Name for cephalexin
Sponsor	Trials
Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	5
Eli Lilly and Company	5
GlaxoSmithKline	3

Sponsor Type

Sponsor Type for cephalexin
Sponsor	Trials
Other	94
Industry	21
NIH	6

Cephalexin Clinical Trials Update and Market Forecast: Pipeline Signals, Patent/Regulatory Overhang, and Revenue Projection

Last updated: May 20, 2026

Cephalexin is an off-patent, widely genericized first-generation cephalosporin. The clinical-trial signal is concentrated in formulation, alternative dosing/administration studies, and stewardship-driven use cases, rather than late-stage, de novo antibio-resistance moats. Commercial upside in major markets is constrained by low unit pricing and sustained generic competition, so revenue projections track population need, guideline-driven use, and government/procurement dynamics rather than novel mechanism differentiation.

---

What is the current clinical trials landscape for cephalexin?

Bottom line: Recent cephalexin clinical activity is dominated by small-to-mid sized studies (bioequivalence, pediatric dosing, safety/PK, and real-world or stewardship-adjacent clinical endpoints). Late-stage Phase 3 “new drug” programs are rare in the US/EU for cephalexin because the molecule is entrenched as a generic antibiotic.

Trial archetypes showing up in cephalexin searches

• Pharmacokinetics and bridging: pediatric vs adult exposures, food-effect and formulation comparisons, and dose normalization.
• Bioequivalence (BE) and formulation: immediate vs extended or taste-masked oral products, suspension stability, and improved tolerability.
• Safety/tolerability: adverse event characterization in specific populations (pediatric, renal impairment strata, allergy-history subgroups).
• Stewardship and guideline alignment: non-inferiority comparisons vs other commonly used oral antibiotics for selected uncomplicated infections.

How to interpret “clinical trials update” for cephalexin

For off-patent antibacterials, clinical trial updates generally correlate to:

• New product launches by existing generic makers (reformulation, new strength, new dosage form).
• Regulatory BE packages supporting ANDA amendments or label expansions.
• Geographic re-entries into hospital formularies through procurement tenders.

No durable, mechanism-based exclusivity typically follows from these efforts because the foundational compound is not protected by a modern composition-of-matter estate in major jurisdictions.

Market implication: Pipeline-derived pricing power is limited. The main market impact is share gains by better-tolerated formulations or faster supply chains.

---

Which clinical trials are recruiting or active for cephalexin right now?

Bottom line: Specific “recruiting/active” listings must be pulled from registries (ClinicalTrials.gov, EUCTR, WHO ICTRP). Without live registry access in this session, a verified current list cannot be produced without risking factual errors.

---

When do cephalexin clinical trial results typically translate into commercial launches?

Bottom line: For generics and label extensions, the commercial translation cycle is usually:

• Phase 1/BE completion → ANDA launch readiness or supplemental filing
• BE/PK data acceptance → time to manufacturing scale-up and procurement onboarding

Typical timeline pattern (generic antibiotics)

• BE/studies completion: often 3 to 12 months from first dosing in small protocols
• Regulatory throughput: 3 to 9 months from data collation into a supplement/AND A batch package, depending on completeness
• Commercial onboarding: procurement cycles can add 1 to 6 quarters

Market implication: Even when a trial finishes, revenue lift is usually gradual and tied to contracting wins, not immediate pricing shifts.

---

What patents protect cephalexin in 2026, and how strong is the patent estate?

Bottom line: The cephalexin molecule is old and off-patent in major markets. Contemporary patent protection, where it exists, is usually limited to specific formulations, manufacturing processes, or pediatric/specific-use labeling efforts tied to particular product presentations rather than the active ingredient itself.

Patent estate structure for off-patent antibacterials

• Composition-of-matter for the API: generally expired.
• Formulation patents: cover particular excipient systems, coating/taste-masking, or stability-improved suspensions.
• Process patents: cover crystallization, polymorph control, or specific manufacturing steps.
• Method-of-use patents: comparatively rare for cephalexin because standard indications are well-established and often sit outside strong exclusivity zones.

Commercial implication: Patent strength tends to be fragmentary across companies. It rarely changes the overall pricing ceiling for cephalexin generics.

---

What is the Orange Book status of cephalexin in the US?

Bottom line: Cephalexin is widely listed in the FDA Orange Book with numerous ANDA entries. The “active” status is typically the result of ongoing exclusivity remnants for specific products or supplements, not sustained API-level protection.

Orange Book dynamics that matter

• Multiple ANDAs reduce the practical value of any single formulation patent.
• Listed patents often expire on a rolling basis depending on filing dates and continuation strategy by individual ANDA holders.
• Exclusivity (if any) is generally product-specific, short relative to the long tail of cephalexin demand.

Market implication: Competitive entry risk is structurally high, with the market already saturated.

---

When does cephalexin lose exclusivity in key markets?

Bottom line: Any exclusivity is product-specific and typically short-lived; cephalexin’s active ingredient exclusivity ended years ago in major jurisdictions. Remaining exclusivity tends to relate to:

• specific strengths/dosage forms,
• specific labeling,
• and limited formulation or process innovations.

Without a live Orange Book and national patent register pull for each listed product, a credible “date-by-date” exclusivity table cannot be produced without risking inaccuracies.

---

Which companies are challenging cephalexin patents via Paragraph IV?

Bottom line: Patent challenges for cephalexin are historically common for older generics, but the current active litigation set must be verified with up-to-date FDA Orange Book patent lists and court dockets. A factual “current challengers” list cannot be compiled reliably in this session without registry access.

---

What generic entry risks exist for cephalexin?

Bottom line: Entry risk is low in the sense that the market is already open and highly genericized, but it is high in the sense that supply and pricing are exposed to new entrants and manufacturing expansions that can lead to periodic share shifts.

Practical entry drivers

• ANDA availability and cost: once BE requirements are met and manufacturing is scaled, marginal entrants can price aggressively.
• Supply chain reliability: shortages or capacity constraints can temporarily tighten supply and lift price.
• Procurement pricing resets: government/large institutional purchasing cycles can change the effective realized price.

Market implication: The “risk” is less about IP blocking and more about pricing volatility and contracting dynamics.

---

How do cephalexin clinical studies affect labeling, dosing, and adoption?

Bottom line: For cephalexin, clinical updates mostly influence:

• pediatric dosing accuracy (PK-based label language),
• tolerability (formulation choice),
• and administrative ease (suspension stability, reconstitution guidance, palatability/taste-masking).

Adoption channels impacted

• Pediatric formularies: adoption rises with better suspension stability and tolerability.
• Stewardship programs: standardized dosing tables and safer administration guidance can improve compliance.
• Hospital systems: procurement and formulary selection respond to supply reliability and cost.

---

How does cephalexin compare with other oral antibiotics for the same indications?

Bottom line: Cephalexin competes broadly in uncomplicated skin and soft tissue infections, streptococcal pharyngitis, and other common outpatient bacterial indications where clinicians choose among beta-lactams (amoxicillin, dicloxacillin, cephalexin), macrolides, and sometimes clindamycin or doxycycline. Its differentiator is typically tolerability and narrow-spectrum beta-lactam positioning rather than breakthrough outcomes.

Market impact of comparative positioning

• Guidelines and resistance patterns shift mix over time, but cephalexin generally remains a default option in beta-lactam pathways.
• Allergy labeling influences exclusion in penicillin-allergy populations, which can reduce addressable demand.
• Seasonality in respiratory and skin infection burden affects annual volumes.

---

What dosage forms and formulations are driving cephalexin demand?

Bottom line: Demand is spread across capsules and tablets for adults and suspensions for pediatrics. Formulation improvements that reduce taste issues, improve stability, and simplify administration can drive share shifts among generic manufacturers even absent API exclusivity.

Formulation levers that matter in procurement

• suspension reconstitution ease and stability,
• shelf life under local storage conditions,
• consistent particle size/crystallinity and dissolution performance,
• pediatric palatability and adherence.

---

What is the commercial outlook for cephalexin in 2026 and beyond?

Bottom line: Cephalexin’s market outlook is steady-to-moderate growth in volume with constrained value growth due to generic price competition. Revenue tends to track:

• population needs,
• outpatient and pediatric visit volumes,
• and payor reimbursement and tender price resets.

Revenue projection framework (what to watch)

• US outpatient antibiotic prescribing trend: stewardship can cap growth; shifts toward or away from first-generation cephalosporins drive mix.
• Pediatric demand stability: suspension-dominant markets are less sensitive to immediate payer policy changes than broad adult formulations.
• Manufacturing capacity: disruptions lift prices temporarily; resolution returns pricing to a floor.

Projection direction (qualitative):

• Units: stable to slightly up with demographic and prescribing patterns.
• Average realized price: likely flat to down unless procurement tightens or supply shocks occur.
• Industry revenue: modest growth at best, primarily from volume and mix rather than pricing.

A numeric projection cannot be responsibly stated without verified baseline sales, country segmentation, and current pricing trends.

---

Where is cephalexin most exposed to regulatory actions and supply disruptions?

Bottom line: Cephalexin is exposed to standard antibiotic manufacturing risk. Regulatory risk is generally tied to:

• facility inspections,
• quality system findings,
• and potential recalls for specific lots or dosage forms.

Likely operational risk hotspots

• high-volume oral solid supply chains (tablets/capsules),
• pediatric suspension manufacturing (more complex formulation and fill-finish),
• reconstitution stability verification and packaging compliance.

Market implication: Risk events tend to create temporary price spikes and share shifts, not long-term product-level differentiation.

---

Key Takeaways

• Cephalexin’s clinical pipeline is mostly BE/PK/formulation and incremental pediatric/safety studies rather than new mechanism development.
• Patent and exclusivity leverage is limited and product-specific, with broad generic saturation across major markets.
• Market value growth is constrained by low pricing and tender-driven competition; near-term dynamics are driven by volume, mix, and supply reliability more than innovation.
• The practical “update” for cephalexin is regulatory and formulation-led: launches, supplements, and procurement wins.

---

FAQs

1) What are the most common cephalexin dosing studies in pediatric populations?

PK and bridging studies that support suspension dosing accuracy and safety monitoring in age-stratified pediatric cohorts.

2) Do cephalexin formulation patents materially delay generic entry?

Usually not at the API level; formulation or process patents can delay specific product variants but rarely slow overall cephalexin availability.

3) How does antibiotic stewardship affect cephalexin prescribing volumes?

Stewardship programs generally cap broad antibiotic use; cephalexin remains used where guidelines support beta-lactam options for specific uncomplicated infections.

4) What dosage form changes most influence adherence for cephalexin?

Suspension palatability, stability, and ease of reconstitution tend to influence pediatric adherence and caregiver preference.

5) What supply events historically move cephalexin prices?

Manufacturing capacity constraints and quality-related recalls can create temporary shortages that lift prices until normal supply returns.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. ClinicalTrials.gov. Cephalexin (keyword search). National Library of Medicine.
3. EMA. EU Clinical Trials Register. Cephalexin (keyword search). European Medicines Agency.